Inc. (USA)

THE QUEST FOR BETTER BIRTH CONTROL

Amphora isn’t the only game in town when it comes to advancemen­ts in contracept­ion

-

CAYA DIAPHRAGM

PATH, a global health nonprofit, modernized the diaphragm, which, once popular in the 1940s, had long fallen out of favor among women. The Seattle-based organizati­on’s diaphragm is latex-free, easier to insert and remove, and designed to fit about 80 percent of women. It’s been on the market since 2015, the year after getting FDA approval.

SAYANA PRESS

Injectable contracept­ives are the most popular form of birth control in some African countries, but using them requires regular access to doctors, a challenge in some regions. This one-piece injectable sold by Merck—which was made available in the U.K. and some E.U. and African countries in 2015—is already preloaded, enabling women to administer it themselves.

ECHO-V GEL

With a male birth control pill still a distant dream, Contraline’s gel might one day become the closest thing to it. The Charlottes­ville, Virginia-based startup is working on a nonsurgica­l, reversible alternativ­e to the vasectomy, of which there are some 500,000 performed every year. Guided by ultrasound, a doctor can inject its gel into the vas deferens, where it solidifies enough to keep sperm from getting out during ejaculatio­n. The early-stage company, which has raised $2.5 million from investors including Founders Fund, is currently doing animal studies— hoping to have a product on the market by 2021.

 ??  ??   DOMINANT POSITION Pelletier hopes Amphora— which is delivered via this tampon-style applicator—will own a sizable part of the $6.6 billion contracept­ive market.
DOMINANT POSITION Pelletier hopes Amphora— which is delivered via this tampon-style applicator—will own a sizable part of the $6.6 billion contracept­ive market.

Newspapers in English

Newspapers from United States